

## INFORMATION DISCLOSURE STATEMENT CERTIFICATION

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☒ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

Respectfully submitted,  
Arnold & Porter LLP

Dated: March 10, 2010

By: Barrie Bell  
Barrie Bell, Reg. No. 46,740

PATENT

Attorney Docket No. GNE-0290 RIC1P4C1 US( 24126.172)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Ellen Filvaroff	)	
	)	Group Art Unit: 1646
Application No.: 10/617,573	)	
	)	Examiner: Jiang, Dong
Filed: July 11, 2003	)	
	)	
For: Pharmaceutical compositions, kits and therapeutic	)	
uses of antagonist antibodies to IL-17E	)	

**PETITION TO CONSIDER INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(d)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

Sir:


Applicant hereby Petition the Commissioner to consider the references cited in the attached Information Disclosure Statement. The Information Disclosure Statement is being submitted after receipt of a Final Official Action or Notice of Allowance, but before payment of the issue fee, and is therefore accompanied by this Petition to Consider in accordance with the provisions of 37 C.F.R. 1.97(d). Also attached hereto is a Certification as required by this paragraph.

Please charge the Petition fee of \$130.00 under 37 CFR 1.17(i) to Deposit Account No. 50-2387 (Docket No. GNE-0290 RIC1P4C1 (24126.172)).

The Commissioner is authorized to charge any additional fees which may be required, including petition fees and extension of time fees, or credit any overpayment to Deposit Account No. 50-2387 (Docket No. GNE-0290 RIC1P4C1 (24126.172)). A duplicate copy of this paper is enclosed.

Respectfully submitted,  
Arnold & Porter LLP

Date: March 10, 2010

By:   
Barrie Bell, Reg. No. 46,740

Arnold & Porter LLP  
555 Twelfth Street, NW  
Washington, D.C. 20004-1206  
Customer No. 35489

PATENT

Attorney Docket No. GNE-0290 R1C1P4C1 (24126.172) US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application	)	<u>PATENT APPLICATION</u>
	)	
Inventor(s): Ellen Filvaroff	)	
	)	Art Unit: 1646
Application No.: 10/617,573	)	
	)	Examiner: Jiang, Dong
Filed: July 11, 2003	)	
	)	
Title: Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E	)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and foreign patent, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609. Each of these references listed on the attached form PTO-1449 was cited in the EP Opposition from the related EP 1 076 703 dated 01/22/2009.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$130.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-2387 (Docket No. GNE-0290 RIC1P4C1 (24126.172)).

Respectfully submitted,  
Arnold & Porter LLP

Dated: March 10, 2010

By Barrie Bell  
Barrie Bell, Reg. No. 46,740

Arnold & Porter LLP  
555 Twelfth Street, NW  
Washington, DC 20004-1206  
Customer No. 35489